You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中生製藥(01177.HK)「派安普利」於腫瘤免疫治療學會年會以突破性成果形式發布
阿思達克 11-12 17:22
中國生物製藥(01177.HK)公布,集團與康方生物科技共同開發及商業化的抗PD-1單抗藥物「派安普利」用於治療復發或難治性經典型霍奇金淋巴瘤最新安全性及有效性數據在第35屆腫瘤免疫治療學會年會上以突破性成果(Late Breaking Abstract)形式發布,該研究顯示,派安普利單抗在至少進行了2次療效評估的r/r cHL受試者中表現出顯著的臨床獲益。其中,客觀緩解率(ORR)達到83.6%,完全緩解率(CR)達到49.3%,明顯高於歷史對照,且優於目前有條件獲批上市的PD-1單抗已公布數據。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account